Role of ST2 biomarker for the evaluation of myocardial remodeling in patients with ischemic heart failure with preserved ejection fraction

Aim. 1) To study the role of soluble ST2 (sST2) in evaluation of left ventricular (LV) myocardial remodeling and 2) to evaluate the predictive value of sST2 for development of adverse cardiovascular events (CVE) during 12 months following myocardial revascularization in patients with ischemic heart disease (IHD) and chronic heart failure (CHF) with preserved LV ejection fraction (EF). Materials and methods. The study included 55 patients (42 men) with IHD and NYHA FC I-III CHF with LV EF 63 [59; 65] % aged 65 [58; 69] who were scheduled for myocardial revascularization. Echocardiographic evaluation of myocardial stress and myocardial remodeling indexes was performed for all patients. Content of sST2 was measured using enzyme immunoassay. Results. Group 1 included patients with sST2 overexpression (≥35 ng/ml) (n=26; sST2-43.75 ng/ml) and group 2 - patients with the sST2 expression <35 ng/ml (n=29; sST2-25.8 ng/ml). LV EF was lower by 5.8% (р=0.017) in group 1 than in group 2. Cardiovascular resistance was 6.7% higher (р=0.022) in group 1 than in group 2. Indexes of myocardial stress were higher by 8.2% (р=0.026) during systole and by 7.8% (р=0.027) during diastole in group 1 compared with group 2. During 12 months following myocardial revascularization, the incidence of adverse CVEs was significantly higher in group 1 (67.59% of cases, р=0.006) than in group 2 (17.24% of cases). Levels of sST2 correlated with EchoCG indexes of LV structure and function (р<0.05): sST2 inversely correlated with LV EF (r= -0.301) and end systolic elasticity (r= -0.346), and positively correlated with end systolic volume (r=0.453), end diastolic volume (r=0.396), end systolic dimension (r=0.373), end diastolic dimension (r=0.288), cardiovascular resistance (r=0.286), and LV myocardial mass (r=0.346). Conclusion. In IHD patients with CHF and preserved LV EF, increased levels of sST2 were correlated with markers of LV structure and function. The study showed an interrelationship between myocardial stress and processes of myocardial ischemic remodeling and sST2 levels in patients with IHD and CHF.

растворимый ST2-РЕЦЕптор, ишемическая болезнь сердца, ремоделирование миокарда, реваскуляризация миокарда, сердечная недостаточность, прогнозирование, soluble ST2 receptor, coronary heart disease, myocardial remodeling, myocardial revascularization, heart failure, prediction

1. Нечесова Т. А., Коробко И. Ю., Кузнецова Н. И. Ремоделирование ЛЖ: патогенез и методы оценки. Медицинские новости. 2008, (11):7-13.

2. Буховец И. Л., Ворожцова И. Н., Лавров А. Г., Гракова Е. В., Сазонова С. И., Ахмедов Ш. Д. и др. Клеточная кардиомиопластика в хирургическом лечении больных ИБС и постинфарктным кардиосклерозом: результаты 3-летнего наблюдения. Сибирский медицинский журнал (г Томск). 2011,26, (4-1):51-8.

3. Тепляков А. Т., Тарасов Н. И., Торим Ю. Ю., Крылов А. Л., Кривонос Д. С., Рыбальченко Е. В. Сравнительная оценка антиишемической эффективности коронарного стентирования у больных ИБС со сниженной ФВ ЛЖ и консервативной медикаментозной терапии. Сибирский медицинский журнал (г Томск). 2008,23 (1-2):5-10.

4. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J. et al. The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease). Circulation. 2006,114 (25):2850-70. DOI:10.1161/CIR-CULATIONAHA. 106.655688

5. Беленков Ю. Н., Мареев В. Ю. Сердечно-сосудистый континуум. Журнал С.Н. 2002;3 (1):7-11.

6. Агеев Ф. Т., Овчинников А. Г. Диастолическая дисфункция как проявление ремоделирования сердца. Журнал С.Н. 2002;3 (4):190-5.

7. Burchfield JS, Xie M., Hill J.A. Pathological Ventricular Remodeling: Mechanisms: Part 1 of 2. Circulation. 2013;128 (4):388-400. DOI:10.1161/CIRCULATIONAHA. 113.001878

8. Тепляков А. Т., Калюжин В. В. Ремоделирование сердца: связь с развитием систолической и диастолической дисфункцией. Коронарная и СН: коллективная монография под общей редакцией РС Карпова - Томск: STT. 2005;229-32.

9. Cohn JN, Ferrari R., Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J. Am Coll Cardiol. 2000;35 (3):569-82. PMID:10716457

10. Скворцов А. А., Протасов В. Н., Нарусов О. Ю., Кошкина Д. Е., Осмоловская Ю. Ф., Кузнецова Т. В. и др. Растворимый рецептор подавления туморогенности 2-го типа против копептина: прямое сравнение значения определения новых биомаркеров для прогноза у больных с декомпенсированной С.Н. Кардиология. 2017;17 (9):20-33. DOI:10.18087/cardio. 2017.9.10028

11. Broch K., Ueland T., Nymo SH, Kjekshus J., Hulthe J., Muntendam P. et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. European Journal of Heart Failure. 2012;14 (3):268-77. DOI:10.1093/eurjhf/hfs006

12. Weinberg EO, Shimpo M., De Keulenaer GW, MacGillivray C., Tominaga S., Solomon SD et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106 (23):2961-6. PMID:12460879

13. Weir R.A.P., Miller AM, Murphy GEJ, Clements S., Steedman T., Connell JMC et al. Serum Soluble ST2. Journal of the American College of Cardiology. 2010;55 (3):243-50. DOI:10.1016/j. jacc. 2009.08.047

14. Дылева Ю. А., Груздева О. В., Акбашева О. Е., Учасова Е. Г., Федорова Н. В., Чернобай А. Г. и др. Значение стимулирующего фактора роста ST2 и NT-proBNP в оценке постинфарктного ремоделирования сердца. Российский Кардиологический Журнал. 2015;20 (12):63-71.

15. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013;14 (7):379-472. DOI:10.18087/rhfj. 2013.7.1860

16. Yancy CW, Jessup M., Bozkurt B., Butler J., Casey DE, Drazner MH et al. 2013 ACCF / AHA guideline for the management ofheart failure: a re port of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am Coll Cardiol. 2013,62 (16):e147-239. DOI:10.1016/j. jacc. 2013.05.019

17. Lang RM, Badano LP, Mor-Avi V., Afilalo J., Armstrong A., Ernande L. et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging. 2015,16 (3):233-71.DOI:10.1093/ehjci/jev014

18. Kim M-S, Jeong T-D, Han S-B, Min W-K, Kim J-J. Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency. Journal ofKorean Medical Science. 2015,30 (5):569. DOI:10.3346/jkms. 2015.30.5.569

19. Januzzi JL, Pascual-Figal D., Daniels L.B. ST2 Testing for Chronic Heart Failure Therapy Monitoring: The International ST2 Consensus Panel. The American Journal of Cardiology. 2015,115 (7):70B-75B. DOI:10.1016/j. amjcard. 2015.01.044

20. Gaggin HK, Szymonifka J., Bhardwaj A., Belcher A., De Berardinis B., Motiwala S. et al. Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T. Measurements in Patients With Chronic Heart Failure. JACC: Heart Failure. 2014,2 (1):65-72. DOI:10.1016/j. jchf. 2013.10.005

21. Kuwahara F., Kai H., Tokuda K., Takeya M., Takeshita A., Egashira K. et al. Hypertensive Myocardial Fibrosis and Diastolic Dysfunction: Another Model of Inflammation? Hypertension. 2004,43 (4):739-45. DOI:10.1161/01. HYP. 0000118584.33350.7d

22. Glezeva N., Baugh J.A. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Failure Reviews. 2014,19 (5):681-94. DOI:10.1007/s10741-013-9405-8

23. Levy D., Salomon M., DAgostino RB, Belanger AJ, Kannel W.B. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994,90 (4):1786-93. PMID:7923663

24. Хайрутдинова Г. М., Галявич А. С. Диагностические критерии ремоделирования ЛЖ у больных после перенесенного ИМ с зубцом Q. Практическая медицина. 2011,4 (52):75-9.

25. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, Januzzi J.L. Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea. Circulation: Heart Failure. 2009,2 (4):311-9. DOI:10.1161 /CIRCHEARTFAILURE. 108.833707

26. Eschalier R., Fertin M., Fay R., Bauters C., Zannad F., Pinet F. et al. Extracellular Matrix Turnover Biomarkers Predict Long-Term Left Ventricular Remodeling After Myocardial Infarction: Insights From the REVE-2 Study. Circulation: Heart Failure. 2013,6 (6):1199-205. DOI: 10.1161 /CIRCHEARTFAILURE. 113.000403

27. Giannessi D. Multimarker approach for heart failure management: Perspectives and limitations. Pharmacological Research. 2011,64 (1):11-24. DOI:10.1016/j. phrs. 2011.03.006

28. Rehman SU, Mueller T, Januzzi JL. Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure. Journal of the American College of Cardiology. 2008,52 (18):1458 65. DOI:10.1016/j. jacc. 2008.07.042

29. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS et al. Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. Clinical Chemistry. 2012,58 (1):257 66. DOI:10.1373/clinchem. 2011.173369

30. Socrates T, DeFilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M et al. Interleukin family member ST2 and mortality in acute dyspnoea: ST2 as a predictor ofmortality in dyspnoeic patients. Journal of Internal Medicine. 2010,268(5):493-500. DOI:10.1111/ j.1365-2796.2010.02263.x